Protein degraders: chasing undruggable targets
BioPharma Drive: Drug Pricing
JULY 8, 2025
Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise. In their 2001 paper, Crews, Deshaies and others described how synthetic molecules could attach ubiquitins to unwanted cell parts.
Let's personalize your content